Background: Soluble CD40 ligand (sCD40L) levels are increased in various inflammatory states, including human immunodeficiency virus (HIV) infection. sCD40L exists in both monomeric and multimeric forms, however, the majority of circulating sCD40L is monomeric. sCD40L is predominantly released by activated platelets, which we have previously shown are increased during antiretroviral-treated HIV disease. In this study we tested the hypothesis that monomeric sCD40L suppresses dendritic cell (DC) function, thus contributing to immune suppression during HIV infection. Methodology: We compared the effects of monomeric versus multimeric sCD40L on monocyte-derived DC maturation after overnight stimulation and cytokine expression following subsequent overnight Toll-like receptor (TLR) stimulation via FACS analysis and cytokine bead arrays. We also evaluated T cell proliferation and Th1-skewing capacity of DCs exposed to monomeric versus multimeric sCD40L following co-culture with carboxyfluorescein succinimidyl ester (CFSE) labeled naive CD4+ T cells. Results: We found that only sCD40L multimer, but not monomer, matures DCs after overnight incubation, as measured by CD86 surface expression. Furthermore, DCs incubated with sCD40L multimer, but not monomer, enhance T cell proliferation. However, both monomeric and multimeric forms of sCD40L suppress the production of the Th-1 skewing cytokine, IL-12, by DCs in the setting of subsequent TLR stimulation with Poly ICLC (fold change decrease by 3 and 5 respectively). DCs incubated with either sCD40L monomer or multimer suppress Th-1 skewing of naive CD4+ T cells in the setting of subsequent TLR stimulation with Poly ICLC, as measured by interferon-gamma production. Conclusions: In summary, multimeric sCD40L activates DCs to become potent antigen presenting cells and appropriately downmodulates the ability of DCs to be subsequently stimulated with TLR ligands after initial activation, whereas the predominant monomeric form of sCD40L plays a solely immunosuppressive role on DC function. Thus, elevated levels of monomeric sCD40L during HIV infection may hinder the ability of DCs to stimulate adaptive responses during the course of disease. Future mechanistic studies will define differential signaling pathways induced by monomeric versus multimeric sCD40L in DCs. Future clinical trials will test whether anti-platelet therapy may reduce circulating sCD40L and improve DC function.